medi-cal semaglutide vs Tirzepatide for Medical Weight Loss Medi-Cal users on GLP1: what

As shown in Table 168, for the six specialty groups that account for the most ASC utilization and spending, we estimate that the final update to ASC payment rates for CY 2026 would result in a 4 percent increase in aggregate payment amounts for eye and ocular adnexa procedures, a 2 percent increase in aggregate payment amounts for musculoskeletal system procedures, a 2 percent increase in aggregate payment amounts for nervous system procedures, a 3 percent increase in aggregate payment amounts for digestive system procedures, a 5 percent increase in aggregate payment amounts for cardiovascular system procedures, and a 12 percent increase in aggregate payment amounts for genitourinary system procedures

The patients eventual relapse upon restarting Ozempic proves the drug is the pathological driver, perpetually compromising the VNC and preventing therapeutic gain

It was first identified in human plasma and has since become a major subject of interest in regenerative biology, tissue engineering, and extracellular matrix research

For research-protocol design, the practical implication is that dual- and triple-agonist compounds are not interchangeable with stacks of single-agonist components

remains experimental and unapproved